**Report and Accounts** 31 March 2022 ## **Research That Saves Lives** leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Leukaemia and Myeloma Research UK Ltd Company Limited by guarantee Registered number 09481278 ## **Research That Saves Lives** Leukaemia and Myeloma Research UK Ltd Unit 127, North Mersey Business Centre, Woodward Rd, Knowsley Industrial Park, Liverpool, Merseyside, L33 7UY Tel: 0800 368 7309 Web: www.leukaemiamyelomaresearchuk.org Email: cs@leukaemiamyelomaresearchuk.org _Charity Number 1161622 Company Number 09481278_ Follow us on Twitter: **https://twitter.com/lmruk_org** Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org** MODEL CELL BIOBANK Together we can beat cancer Annual Report 2022 ## **Table of contents** |�����������������������������������������������������������������������������������������������������������������|�| |---|---| |����������������������������������������������������������������������������������������������������������������|�| |Charitable Activities........................................................................................|5| |����������������������������������������������������������������������������������������������������������|�| |����������������������������������������������������������������������������������������������������|�| |MCB Service..................................................................................................|9| |����������������������������������������������������������������������������������������������|�| |Case Study....................................................................................................|11| |Research Priorities.......................................................................................|12| |���������������������������������������������������������**����������������������������������������**|**��**| |�������������������������������������������������������������������������**����������������������������������������**|**��**| |���������������������������������������������������������������**�����������������������������������������**|**��**| |Accounts ..............................................................**.........................................**|**15**| https://leukaemiamyelomaresearchuk.org 2 ## **About Us** _Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood ������������������������������������������������������������������������������������ cancer regardless of how long it might take._ Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment. Unfortunately, blood cancer affects a large number of �������������������������� someone in the UK is told they have a blood cancer. That’s around 110 people per ����������������������������� ����������������������������� leukaemia deaths every year, �������������������� We are aiming to become the UK’s leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children’s future health by storing their cord blood stem cells at the time of birth. ������������������������� cancers of the blood; they are lymphoma, leukaemia and myeloma. The blood is made up of three different types of cells: ������������������������������� research into blood cancers ���������������������������� cell therapies ������������������������������ the oxygen around the body ������������������������������� and stop infections ��������������������������� blood to clot ��������������������������� blood cancers and treatment options ������������������������������ offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby’s umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they’re a suitable match. This service is called Model Cell Biobank (MCB). The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant. In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by: � ����������������� ## **Stem Cells** _In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues._ Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside. For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain. ## **Where are stem cells found?** There are four known accessible sources of autologous adult stem cells in humans: ���������������������������� harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic. ����������������������� extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor. ������������������������������� which requires extraction by liposuction cancers, such as sickle cell anaemia and aplastic anaemia. ������������������������������ stem cells can be collected from the umbilical cord blood just after birth. For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia’s, the treatments use allogeneic stem cell transplants (someone else’s stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease. ## **What can stem cells be used for today?** There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive. However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia’s and solid tumours) that are treated using autologous stem cells (using your own stem cells). There are other blood disorders that can be treated with stem cells that aren’t https://leukaemiamyelomaresearchuk.org � ## **Charitable Activities** Providing Information can be used to treat blood cancer patients. All grant applications are reviewed by the Charity’s Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC. Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices. Fundraising Activities Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the ������������������������� recycling. It also continues to raise valuable funds for the charities work. low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease. We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge. The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells. In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has ������������������������������ support our services and help ��������������������������� Medical Research Leukaemia & Myeloma Research UK allocate research grants to those who uphold our primary objectives. These ����������������������������� particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. ����������������������������� cell storage service to promote ‘biological insurance’ - where a child’s cord-blood stem cells Model Cell Biobank Service This service was established to support families who are on are stored at the time of birth. The service is offered free of charge to families on ��������������������������� service is offered to low income families. Our current funding priorities are to advance understanding of stem cells and how they 5 ����������������� ## **Chairman’s Report** One of our key focuses over the last year has been to widen awareness of blood cancer. We have achieved this in a number of ways. shared quotes from the West Lancashire and Merseyside Myeloma Support Group about living with the disease. It also shared facts and statistics about myeloma. UK Charity Week was celebrated in December for �������������������������� partner. The charity now has a regular section in the organisers Charity Today E-magazine where we highlight facts about blood cancer , the MCB service, and celebrate our amazing fundraisers. In May, the Charity engaged in the World Blood Cancer Day sharing blood cancer statistics and highlighting how people support us. Finally, I would like to take this opportunity to thank all our volunteers and fundraisers for all the amazing work they have done throughout the year. Without their support we wouldn’t be able to continue to offer the services that we do. In January, we launched the School Textile Recycling Scheme in the Liverpool and Greater Manchester areas. The team have been working hard to engage with schools and spread the message. Combined with this, in June we marked National Myeloma Awareness week, during which the Charity highlighted common signs and symptoms to look out for. ����������������������������� was marked by Myeloma Awareness Month. The Charity promoted its annual March for Myeloma campaign and In November, we celebrated World Cord Blood Day. We collated 80 facts about cord blood and produced a special edition of our E-newsletter. **Sergey Vinogradov** Chair, Leukaemia and Myeloma Research UK Ltd https://leukaemiamyelomaresearchuk.org � ## **Operation Director’s Report** Morgan was the recipient of research grant to support his work into Cell Signalling Abnormalities in Leukaemia Cells. It has been a challenging year as the country emerges from the pandemic. However, we are truly grateful to our fantastic fundraisers who have ventured out to challenge themselves whilst raising vital funds for the Charity. We were fortunate to be ������������������ corporate funding from Aviva ‘Pennies for Good’ ��������������������������� our work. Following this in December, the Charity received £10,000 from Box Power - ��������������������������� �������������������������� were overwhelmed by the generousity of Aviva and Box ��������������������������� funding, which will help us to make a huge difference in ��������������������������� ������������������ To give a few examples, we have had a father and son run ���������������������������� their wife and mum, who sadly passed away from leukaemia. designed to inform the public about the important work we do, protecting the next generation and the vital stem cell research we invest in to prevent people dying from blood cancer. Students have held a Turkish buffet in college. Other fundraisers have done events such as: Man Versus Coast Challenge, cycling Lands End to John O’Groats, running the virtual London Marathon, and taking part in the Snowdonia Trail Marathon. One of our new fundraising ventures was to secure places for riders to participate in the 2022 London to Brighton Ride. This was launched in **----- Start of picture text -----**
Trail Marathon. This was launched in
In November, the Charity September 2021 and I am
We welcomed three new produced a webinar with the �������������������������������
members to the Research and help of one of our fundraisers, all the places by March 22.
Review Committee this year: one of our ambassadors and We are pleased to be working
Dr John Jones, Dr Ceri Bygrave, members of the Research and with Lister Wilder Agriculture
and Dr Salvatore Papa. Dr Rhys Review Committee. This was team of over 50 riders who
� �����������������
**----- End of picture text -----**
**are jo** ining us for this epic **challe** nge. **Our co** rd blood banking service **contin** ues to grow from **streng** th to strength. We **exper** ienced a 50% increase **in enq** uiries and hope that **this w** ill continue over the the **next y** ear ensuring we can **������** ������������������������� **again** st blood cancer. We are extremely grateful to the generous funding received from Fundraising Support who have helped this service support even more families. I would like to say a huge ‘thank you’ to our fundraisers for their hard work and to our hard working staff and partners who have pulled together to make 2021-22 such a huge success. All of our fundraisers are important from cake sales to sky dives - we simply would not be able to run these services without their help. **Dr Joanna Tilley** Operations Director, Leukaemia and Myeloma Research UK Ltd https://leukaemiamyelomaresearchuk.org 8 ## **MCB Service** ## **Overview** **The Model Cell Biobank (MCB)** service allows the storage of a child’s umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson’s disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs. the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks. Biovault Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Biovault has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant. The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing ���������������������� Universal Credit (at least one of these) and must meet the following criteria: Biovault not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of. When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future. ����������������������������� to treat the child, or another member of the family, for a medically attested treatment; ������������������������������ in the immediate family. We recently extended the project to support low-income families by implementing a part funded service for those who have medical history, but **�������������������** The cor **d blood stem cells** are stor **ed on behalf of the** child fo **r 25 years. The mother** is the le **gal guardian of the** cells un **til the child reaches** ������������� **����** 9 ## **Advantages of Cord Blood Stem Cells** Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s. harvested and stored; ## **Client feedback** �������������������������� exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient; “The team at LMRUK were so helpful andknowledgeable – they talked me through the whole process and advised me that as a sibling, there was a 25% chance that Alice’s stem cells would be a match for Lara’s. Craig and I read through all the information on the LMRUK website and decided to apply. (Client) ������������������������������ the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stemcell collection, such as bone marrow; The stem cells in your baby’s cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders. “Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother’s worst nightmare. I am incredibly grateful to have found out about this potentially lifesaving service, and even if we don’t use the stored cord blood stem cells, it is reassuring to know that they will not go to waste.” (Client) ��������������������������� be stored for many years - the longevity of these cells has **����** ����������������������� **year** s later as on as the day **����** ������������������������� **stor** ed. **Cord blood stem cells have many advantages including:** **����������������������������� having already been** https://leukaemiamyelomaresearchuk.org 10 ## **Case Stud – Elaine’s Stor y y** Restaurant owners, Elaine and Peter Kinsella have raised an impressive £15,000 in three months for Leukaemia & Myeloma Research UK (LMRUK), West Lancs and Merseyside Myeloma Support Group (WL&M Myeloma) and the Liverpool Haematology Patient Support Group following Elaine’s myeloma diagnosis last year. ������������������������������ myeloma following a routine blood test after undergoing treatment less than a year before for thyroid cancer. Following initial treatment at Arrowe Park Hospital in Wirral, Elaine had a stem cell transplant at The Clatterbridge Cancer Centre in Liverpool. To support her recovery, she was encouraged to join the WL&M Myeloma Support Group and whilst recovering, she started planning ways she could fundraise to give back to those who helped her throughout her treatment. From October to January 2022, Elaine and Peter who have jointly run the Lunya restaurant in Hanover Street, and Lunyalita on the Albert Docks for over 12 years, invited customers to add an extra pound onto their bill which went into a charity donation pot with the promise ����������������������������� being matched by the couple. wait to get back into the restaurants and see everyone again. ����������������������������� was raised from generous donations and with their personally matched donation, ������������������������ £15,000. This fantastic sum has been split and donated to LMRUK, WL&M Myeloma and the Liverpool Haematology Patient Support Group. Dr Joanna Tilley, Operations Director at LMRUK said: “We are incredibly thankful to Elaine, Peter and their customers who have raised a �������������������������� to support the potentially lifesaving stem cell research ������������������������ ������������������������� and for all. We work closely with the WL&M Myeloma Support Group and know how important donations like these are so that they can continue providing vital support to their members.” Elaine Kinsella said: “We are so thankful to all our customers and friends who have donated money. Now that I am in remission and on the road to recovery, I can’t 11 ����������������� ## **Research Priorities** ## Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. The Trustees’ current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants. Dr Rhys Morgan, a leukaemia researcher and lecturer in Biomedical Science, was awarded a grant for novel research into cell signalling abnormalities in leukaemia cells. “These funds have allowed us to perform an expensive, but highly informative, technique called RNA sequencing (RNAseq) to understand how the cancer promoting protein ������������������������������� gene activation in leukaemia cells, an analysis not previously undertaken before. The research will be undertaken at the University of Sussex. Dr Joanna Tilley, Operations Director at LMRUK said: “Our charity focuses on investing in vital research into the nature, causes, prevention, diagnosis, treatment and cure of blood cancer in the hope of protecting the next generation from this disease. “We’re thrilled to be able to fund Dr Rhys Morgan on the ��������������������������� phase of his fascinating research and we wish him all the best in developing his ������������������������������� ����������������������������� ������������������������� cancer.” ## **Dr Paul Spencer Hole** Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company. ## **Dr Claire Seedhouse** Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham. ## **Dr John Jones** Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital. ## **Dr Rhys Morgan** Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex. ## **Professor Joseph R. Slupsky** Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility. ## **Dr Ceri Bygrave** A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance. ## **Dr Salvatore Papa** An Associate Professor at Leeds University whose research speciality is in lymphoma and myeloma. https://leukaemiamyelomaresearchuk.org 12 ## **Fundraisin and Volunteers g** _With two half marathons under his belt, Daz Martin from Whittington in Shropshire has decided to lace up his running shoes once again and take on his biggest challenge yet._ This July, Daz will be running the epic Xterra Snowdonia Trail Marathon to raise money for Leukaemia & Myeloma Research UK (LMRUK) after his mum, Sue, passed away from Acute Myeloid Leukaemia (AML). After initially going into hospital from suffering with months of getting water infections in April 2021, doctors diagnosed Sue with AML and she was immediately given medication. ������������������������������� ������������������������������� infection after infection and the doctors decided to stop the treatment. Soon after, she was moved into a hospice for palliative care. Three weeks after her diagnosis and just two ��������������������� birthday, Sue passed away leaving behind her husband, John, two sons Daz and Kev, and six grandchildren. “Before my mum’s diagnosis, I wasn’t aware of Acute Myeloid Leukaemia and as a family we were all learning and reading up as much as possible together. “Leukaemia was a form of blood cancer I was familiar with as back in secondary school my best friend, Paul Dart, was diagnosed with it and passed ��������������������������������������� devastating”, said Daz. To raise awareness of the different forms of blood cancer and gather vital funds for charity, ������������������������������������������ ���������������������������������������������� Wales’ highest peak – Snowdon, as part of the Xterra Trail Marathon on 10th July 2022. “The event takes place over one day and starts ������������������������������������������������ Snowdon. The route will take us through all different terrains as we reach the summit to take ���������������������������������������������� ���������������������������������������������� ������������������������������������������������ explained Daz. Over 2,000 runners will be taking part and all hoping to raise money for worthy causes. Daz is aiming ����������������������� LMRUK, he explained: “I wanted to fundraise for a charity that was related to my mum’s illness to help raise awareness of the signs and symptoms of blood cancer, as well as help fund the work ������������������������������������ treatments for patients”. Having previously taken on the Three Peaks ����������������������������������������������� stranger to the gruelling hours of training. “This will be the longest and toughest distance I’ve run in one go, but having already completed the Three Peaks Challenge, half marathons and regularly running 5-10k, and with the amazing support from my partner, Sharon, friends and family, I’m positive I’ll beable to make it to the �������������������������� �� ����������������� ## **Thanks to Funders** - �� Arnold Clark Community Fund - �� The Hobson Charity Ltd - �� The Constance Paterson Foundation - �� Aviva Pennies for Good - �� Lillie Johnson Charitable Trust - �� Thomas Sivewright Catto Charitable Trust - �� Speke Operations - �� Caron Keating Foundation - �� Box Power - �� The Hospital Saturday Fund - �� The Cliff Richard Charitable Trust - �� L and R Gilley Charitable Trust - �� Ian Askew Charitable Trust ## **Staff and Committee Members** ## **Trustees 2021-2022** - �� Sergejs Vinogradov (Chair) - �� Tatjana Vinogradova - �� Victoria Kieran - �� Julija Sidorika ## **Thanks to Individuals and supporters** - �� Best Freelance Design Ltd - �� Biovault Technical Ltd - �� Dr Hannah Hunter – Consultant Haematologist - �� Fundraising Support Ltd ## **Staff Team** - �� Dr Joanna Tilley - Interim Operations Director - �� ��������������������������������������� Call Centre Manager - �� KOR Communications - �� Phlebotomy UK Ltd - �� Research Review Committee - �� Richard Thompson - Call Centre - �� Kate Williams - PT Fundraiser https://leukaemiamyelomaresearchuk.org �� Income and Expenditure Account for the year ended 31st March 20�� ## **Accounts** leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Company Limited by guarantee Registered number 09481278 ## **Accounts 31 March 20��** 15 ## **Leukaemia & Myeloma Research UK Ltd** ## **Report and accounts for the year ended 31 March 2022** ## **Contents** ||**Page**|| |---|---|---| |**Charity information**||1| |**Trustees' Annual Report**||1| |**Statement of directors' responsibilities**||5| |**Independent Examiner's Report**||7| |**_Funds Statements:-_**||| |Statement of Financial Activities||9| |Statement of Financial Activities - Prior Year statement||10| |Movements in funds||12| |Income and Expenditure account||13| |**Balance sheet**||14| |**Notes to the accounts**||15| ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2022** The Trustees present their Report and Accounts for the year ended 31 March 2022, which also comprises the Directors' Report required by the Companies Act 2006. ## **Reference and administrative details** ## _**The charity name.**_ The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd. The charity is also known by its operating name, LMR UK Ltd. ## _**The charity's areas operation and UK charitable registration.**_ The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622. The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland. The charity does not operate in any overseas jurisdictions. ## _**Legal structure of the charity**_ The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation. The governing document is dated 10 March 2015 There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law. By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals. 1 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2022** ## **The principal operating address, telephone number, email and web addresses of the charity** Room 127, North Mersey Business Centre Woodward Road, Liverpool Merseyside, L33 7UY Telephone 08003687309 Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/ The registered office of the charity for Companies Act purposes is the same as the operating ## **The Trustees in office on the date the report was approved were:-** Sergejs Vinogradovs Tatjana Vinogradova Julija Sidorika Victoria Kieran ## **The following persons served as Trustees during the year ended 31 March 2022 :-** The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts. All the trustees are also members of the charity. ## **Objects and activities of the charity** ## _**The purposes of the charity as set out in its governing document.**_ The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are: 1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. 2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters. 2 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2022** ## **Structure, governance and management of the charity** ## _**The methods used to recruit and appoint new charity trustees.**_ Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees. Accountants KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT 3 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2022** ## **Financial review** |Restricted Revenue Funds
**Total Funds**
Unrestricted Revenue Funds available for the
general purposes of the charity
**Net income**|**2022**
**£**
30,559
285,330
31,517
316,847|**2021**
**£**
49,918
258,527
27,761
286,288| |---|---|---| ## _**Financial review of the position at the reporting date, 31 March 2022 .**_ Overall surpplus stands at £316,847 and will be distributed in following way: £50,000 for the Reserves; £20,000 for the E-Shop development; £60,000 for Research grants and 186,847 for the charity and MCB development. The trustees consider the financial performance by the charity during the year to have been satisfactory. ## _**Policies on reserves.**_ All the trustees aim to maintain free reserves in unrestricted funds at a level which equates to between two and four months of unrestricted charitable expenditure. The trustees consider that this level will ensure that there are sufficient funds available to cover support and governance costs. Reserves policy will be reviewed annually based on the charity's annual accounts. Based on the results of past year, the Reserves amount is £50,000. ## _**Availability and adequacy of assets of each of the funds**_ The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund. ## **Details of The Independent Examiner** Olivia Higgins Member of Chartered Certified Accountants 255 Poulton Road Wallasey Wirral CH44 4BT 4 ## **Leukaemia & Myeloma Research UK Ltd** Company Registration Number - 09481278 ## **Trustees' Annual Report for the year ended 31 March 2022** ## **Statement of the Directors Trustees' Responsibilities** The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), . In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :- - to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). - select suitable accounting policies and apply them consistently; - make judgements and estimates that are reasonable and prudent; - prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business; - state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year. The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements. 5 L•ukafjmlo & Myeloma Research UK Ltd C¢xnpgny Reghtralrm rts481278 Trustaes. Annual Roport for the year ended 31 March 2022 Mgthod of preparatlon of accounts- Small ci>mpany pvovlslons The flnanc4al Statements are set out on paggs 9 to 33. The financi￿ statemwls have been pryared inWem&nting the FRS 102 SORP (ststen￿nI of Recommended Pwuce for AccounJng and RepKYting by Charilies} 2015, las amend8d by th8 Bulelln issl￿d In October 2018 and to all accounling periods LwInn￿g on or after 181 January 20191, (Thè SORPI, and in accordw￿ ￿1h the FirwKaal RekN)rtlng Standard 102, (effective 1st January 20161 These finandal Slalements have been prepared in accthane8 ￿ Ihg pmwsions in P•115 01 the Coryardes Acl 2006. applicabb to compaF1￿$ Su14￿ lo Ihe smal coMpan￿S regime. This re￿t was ¥prowJ by bo8￿ oftrustee8 onlg Ikcwn6rf2022. TATJANA VINOGRADOVA Dir￿*Or and Tru8lee ## **Leukaemia & Myeloma Research UK Ltd** ## **Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022** I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2022 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15. ## **Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report** As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view. The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination. Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:- a) examine the financial statements of the charity under Section 145 of the Act; b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act. ## **Basis of Independent Examiner's Statement and scope of work undertaken** Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies. I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP. The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below. I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters. 7 Lgukagmia & Myeloma Rosga￿h UK Ltd Independent ExaminePs StstemenL Report and Opinlon Subjed lo the limitation5 upon the scope of my work as detailed above, I have completed tny examination." and can confirm that-_ The acmunts of thu8 charitable r￿MpanY are not required to be audited under Part 16 of th8 Compani8s Act 2006., This 1$ a ￿ptsrt in ￿Spect of an examination Carried out under 145 01 the Ad and in accordan￿ 4trith Diredions given by Charity Commission under section 14515llbl of the Act which may be applicabla., and that no mal8ri21 mallers have tome to my attantion in connection with the examination giving me cau8e lo believe that in any material respect'.- accounting records were not kept in rèspect of the charty as r4uired by Section 386 of the Compani&5 Ad 2006 and Section 130 of The Charities Act 2011". the financial staternents do not accord with those recvrds, tsr the fin8ncial statem8nls do not cornply with the applicabS& requirement5 Gon￿mIng the form and conlenl of accounts sel out in Section 396 of the Companies Act 2006 other than any requirement that the a¢¢ounts give a 'true and lai¢ view. which is not a matter conside￿d as part of an indep&ndenl examination.. have not beèn prepa￿d in attordanee with the mathods and principles s&1 out in the FRS 102 SORP Istalemenl of Recommended Practice for Accounting and Reporting by Chariliesl 2015, las amended by the 8ulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 20191, IThe SORPI. I have no concerns and have come across no other matters in conn8ction with the examination to which attontion should ba drawn in thi5 report in order to enats￿ a proper understanding of th& financial statement5 to be reached. 8i9ngd:. O, 11 Olivia Hig awlndependent Exarniner KBH A￿UntantS Ltd Chartered Gertrfied A¢counlants 255 Poulton Road Walla5ey W1rol CH44 4BT This reportwa5 signed on 12 2022 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022** ## _**Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2022, as required by the Companies Act 2006)**_ |**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
**Income & Endowments from:**
Donations & Legacies
A1
122,209
Charitable activities
A2
17,526
Investments
A4
27
Other
A5
50,109
**Total income**
**A**
**189,871**
**Expenditure on:**
Raising funds
B1
9,095
Charitable activities
B2
153,973
**Total expenditure**
**B**
**163,068**
**Net income for the year**
**26,803**
**Transfers between funds**
**C**
-
**Net income after transfers**
**A-B-C**
**26,803**
**26,803**
**Reconciliation of funds:-**
**E**
**Total funds brought forward**
258,527
**Total funds carried forward**
**285,330**
**SORP**
**Ref**
**Net movement in funds**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
16,418
320
-
-
**16,738**
-
12,982
**12,982**
**3,756**
-
**3,756**
**3,756**
27,761
**31,517**|**Current year**
**Total Funds**
**2022**
**£**
**138,627**
**17,846**
**27**
**50,109**
**206,609**
**9,095**
**166,955**
**176,050**
**30,559**
**-**
**30,559**
**30,559**
**286,288**
**316,847**|**Prior Year**
**Total Funds**
**2021**
**£**
128,400
7,241
187
52,476
**188,304**
3,527
134,859
**138,386**
**49,918**
-
**49,918**
**49,918**
236,370
**286,288**| |---|---|---|---| The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet. A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses. All activities derive from continuing operations **The notes attached on pages 15 to 33 form an integral part of these accounts.** 9 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022** ## **Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP** |**Income & Endowments from:**
Donations & Legacies
A1
Charitable activities
A2
Investments
A4
Other
A5
**Total income**
**A**
**Expenditure on:**
Raising funds
B1
Charitable activities
B2
**Total expenditure**
**B**
**Net income for the year**
**Net income after transfers**
**Reconciliation of funds:-**
**E**
**Total funds brought forward**
**Total funds carried forward**
**Net movement in funds**
**SORP**
**Ref**|**Prior Year**
**Unrestricted**
**Funds**
**2021**
**£**
120,119
7,241
187
52,476
180,023
3,527
131,594
**135,121**
44,902
44,902
**44,902**
213,625
**258,527**

|**Prior Year**
**Restricted**
**Funds**
**2021**
**£**
8,281
-
-
-
-
8,281
-
3,265
**3,265**
5,016
5,016
**5,016**
22,745
**27,761**|**Prior Year**
**Total Funds**
**2021**
**£**
**128,400**
**7,241**
**187**
**52,476**
**188,304**
**3,527**
**134,859**
**138,386**
49,918
49,918
**49,918**
**236,370**
**286,288**| |---|---|---|---| ## **All activities derive from continuing operations** A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.' **The notes attached on pages 15 to 33 form an integral part of these accounts.** 10 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022** **Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use:-** |Funds generated in the year as detailed in the SOFA
**Net resources available to fund charitable activities**|**2022**
**£**
30,559
**30,559**|**2021**
**£**
49,918
**47,418**| |---|---|---| The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals. **The notes attached on pages 15 to 33 form an integral part of these accounts.** 11 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022** ## **Movements in revenue and capital funds for the year ended 31 March 2022** ## **Revenue accumulated funds** |**Unrestricted**
**Funds**
**2022**
**£**
Accumulated funds brought forward
258,527
26,803
**285,330**
(From)/To unrestricted revenue funds
-
**Closing revenue funds**
**285,330**
**Summary of funds**
**Unrestricted**
**and**
**Designated funds**
**2022**
**£**
Revenue accumulated funds
285,330
Recognised gains and losses before
transfers|**Restricted**
**Funds**
**2022**
**£**
27,761
3,756
**31,517**
-
**31,517**
**Restricted**
**Funds**
**2022**
**£**
31,517|**Total**
**Funds**
**2022**
**£**
286,288
30,559
**316,847**
-
**316,847**
**Total**
**Funds**
**2022**
**£**
**316,847**|**Last year**
**Total Funds**
**2021**
**£**
**236,370**
49,918
**286,288**
-
**286,288**
**Last Year**
**Total Funds**
**2021**
**£**
286,288| |---|---|---|---| **The notes attached on pages 15 to 33 form an integral part of these accounts.** 12 ## **Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022** ## **Leukaemia & Myeloma Research UK Ltd Income and Expenditure Account for the year ended 31 March 2022 as required by the Companies Act 2006** |**_Income_**
Income from operations
Interest receivable
Other operating income
**Gross income in the year before exceptional items**
**Gross income in the year including exceptional items**
**_Expenditure_**
Charitable expenditure, excluding depreciation and amortisation
Depreciation and amortisation
Fundraising costs
Governance costs
**Total expenditure in the year**
Tax on surplus on ordinary activities
**Retained surplus for the financial year**
**Net income after tax in the financial year**
**Net income before tax in the financial year**|**2022**
**£**
156,405
27
50,109
**206,609**
**206,609**
165,910
625
9,095
420
**176,050**
**30,559**
-
**30,559**
**30,559**|**2021**
**£**
135,641
187
52,476
**188,304**
**188,304**
133,814
625
3,527
420
**138,386**
**49,918**
-
**49,918**
**49,918**| |---|---|---| All activities derive from continuing operations In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities. ## **The notes attached on pages 15 to 33 form an integral part of these accounts.** 13 Loukaernla & Myelorna Regear¢h UK Ltsl- Balanc• ShB8tas at 31 I￿rGh 2022 2022 2021 FIK•d a88Ot8 Ten01￿$ a￿ets Total •&i•ts 1,250 1.875 1￿75 Cm#1•88818 Stocks Deblor Cash 4t bank and kn hond Toial wrr•nt4Ba818 B1 17￿07 4.432 16.3e1 1,860 270,732 288.753 321,803 Cr•dhorn: •mounl• hllrvJ ¢hwwl¢hlD ono year 10 C1 6,2061 4.34U N•t¢urr•nta¥g9ts 315A07 284,413 ¥16￿47 288288 The totaln9tM￿¢j of th•¢hwlty 4rgfundgd lyjllwfwth ¢h*rlty. o hPAb*S:. R•strlct•d￿￿dS Re$￿thI Rwuè Fthdt 13 D2 31,517 27.761 31.517 27.761 Unr•#trfetad F￿d8 UMesth(X8d R8V8nue 13 D3 285J30 25e.527 285.330 258,¥27 o￿l￿nal¥d Fund¥ ToialeharltyftMd8 316,847 'SORP Rèf Indicated abo¥e 18 the da￿￿ta￿)n of Sh86t a$ 86t out kn the formal SORP d0￿Ments. As requlred by paragTrFth 4.fju of the SORP, ￿ ￿rn￿m fr)rwBrd WMI fotwatd funds abovB have agmeé to SOFA. The dhBdors are 58t1￿ed that Ihe C(￿PAr￿ Is enlM*J to exwnpkn fr(rfn th8 reqwremonl to obtakn an undef8e(*M 477 ofts comp￿leS Ad 20C6. Tht m￿bets ha¥8 rnl Nulred the coMp￿Y to obl*n accord￿ 476of ikne A( Tha dlrectors acknowkndge their rews1)iltse5 fix with ￿ requtrwts ofthe Ctsrnwuè&Ad 2006 th respèet to 8ccounting reurds and prep8r8tknofaceomts. The c*arty18 to Ind8peThYent Examinalon chHrly IBqB&bcffi. of Ihe Ir4epeThl*tht ExawitWV5 ￿ page e. Thè ffnsrtGo1 statemtrnts ha¥& be￿ Fyepated in acy)xdarte wmh Fxthi8kms kn Part 15 oflh8 compa￿95 At# 2CQ6. 8pplcabie to GOrwan￿8 6mo1rwvan￿ TvgTh. TATjAMvI￿GRADoVA Trustee Approve*Jby board cltruslees on 1gfjEeém&&22 Tho atl•ched on pABes Isto 33 lunn an InleyThl pArtolthue accoun1& 14 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## **1 Accounting policies** ## _**Policies relating to the production of the accounts.**_ ## **Basis of preparation and accounting convention** The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice. ## **Risks and future assumptions** The charity is a public benefit entity. This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven. ## _**Policies relating to categories of income and income recognition.**_ ## **Nature of income** Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers. ## **Categories of Income** Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income. Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser. Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange. 15 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## **Income recognition** Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably. Dividends are accrued when the shareholder’s right to receive payment is established. Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met. All income is accounted for gross, before deducting any related fees or costs. ## **Income from legacies** Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met. Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable. Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant. If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities 16 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## **Donated goods, facilities and services** Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets. Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items. In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales. If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense. The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made. The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in _'legacies and donations_ '. Goods donated for resale are included in _'Income from other trading activities'_ The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner. Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity. All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value. ## _**Policies relating to expenditure on goods and services provided to the charity.**_ ## **Allocating costs to activities** Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities. The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :- **Staffing** - on the basis of time spent in connection with any particular activity. **Staffing** - on a per capita basis, based on the number of of people employed within any partiular activity. **Premises related costs** - on the proportion of floor area occupied by a particular activity. **Non specific support costs** - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures **Estimation techniques** used in apportioning costs - give details 17 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## _**Policies relating to assets, liabilities and provisions and other matters.**_ ## **Stocks and work in progress** Stock is valued at the lower of cost and net realisable value. ## **Debtors** Debtors are measured at their recoverable amounts at the balance sheet date. ## **Creditors and provisions** Liabilities are measured at their settlement amount. A liability is recognised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide. ## **2 Liability to taxation** The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities. ## **3 Winding up or dissolution of the charity** If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity. No employees received emoluments (excluding pension costs) in excess of £60,000 per annum. ## **4 Defined contribution pension schemes** Any liabilites and assets associated with the scheme are shown under debtors and creditors. ## **5 Remuneration and payments to Trustees and persons connected with them** No trustees or persons connected with them received any remuneration from the charity, or any related entity. ## **6 Trustees' expenses** There were no Trustees' expenses in the year and in the prior year. 18 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## **7 Tangible fixed assets** |**_Current Year_**
**Cost**
At 1 April 2021
Additions
**At 31 March 2022**
**Depreciation**
At 1 April 2021
Charge for the year
**At 31 March 2022**
**Net book value**
**At 31 March 2022**
**At 31 March 2021**
**8**
**Stocks & Work in Progress**
Stocks before write downs
**9**
**Debtors**
Prepayments and accrued income
Other debtors|**Land and**
**Buildings**
£
-
-
**-**
-
-
**-**
**-**
**-**|**Plant &**
**Machinery**
£
2,500
-
**2,500**
625
625
**1,250**
**1,250**
**1,875**|**Motor**
**Vehicles**
£
-
-
**-**
-
-
**-**
**-**
**-**
**2022**
**£**
17,507
17,507
**2022**
**£**
485
3,947
**4,432**|**Total**
**Total**
£
£
2,500
2,500
-
-
**2,500**
**2,500**
625
625
625
625
**1,250**
**1,250**
**1,250**
**1,250**
**1,875**
**1,875**
**2021**
**£**
16,361
16,361
**2021**
**£**
1,660
-
**1,660**| |---|---|---|---|---| 19 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** |**10 Creditors: amounts falling due within one year**
Trade creditors
Accruals
**11 Income and Expenditure account summary**
**At 1 April 2021**
Surplus after tax for the year
**At 31 March 2022**|**2022**
**£**
3,916
2,290
**6,206**
**2022**
**£**
286,288
30,559
**316,847**|**2021**
**£**
2,470
1,870
**4,340**
**2021**
**£**
236,370
49,918
**286,288**| |---|---|---| ## **12 Particulars of how particular funds are represented by assets and liabilities** |**At 31 March 2022**
Tangible Fixed Assets
Current Assets
Current Liabilities
**At 1 April 2021**
Tangible Fixed Assets
Current Assets
Current Liabilities|**Unrestricted**
**funds**
**£**
1,250
290,286
(6,206)
**285,330**
**Unrestricted**
**funds**
**£**
1,875
260,992
(4,340)
**258,527**|**Designated**
**funds**
**£**
-
-
**-**
**Designated**
**funds**
**£**
-
-
-
**-**|**Restricted**
**funds**
**£**
-
31,517
-
**31,517**
**Restricted**
**funds**
**£**
-
27,761
-
**27,761**|**Total**
**Total**
**Funds**
**Funds**
**£**
**£**
**1,250**
**1,250**
**321,803**
**321,803**
**(6,206)**
**(6,206)**
**316,847**
**316,847**
**Total**
**Total**
**Funds**
**Funds**
**£**
**£**
**1,875**
**1,875**
**288,753**
**288,753**
**(4,340)**
**(4,340)**
**286,288**
**286,288**| |---|---|---|---|---| 20 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## **13 Change in total funds over the year as shown in Note 12 , analysed by individual funds** |**Funds brought**
**forward from**
**2021**
**£**
**_Unrestricted and designated funds:-_**
Unrestricted Revenue Funds
258,527
**Total unrestricted and designated funds**
**258,527**
**_Restricted funds:-_**
Model Cell Biobank
27,761
**Total restricted funds**
**27,761**
**Total charity funds**
**286,288**
**14 Analysis of movements in funds over the year as shown in Note**
**Income**
**2022**
**£**
**_Unrestricted and designated funds:-_**
Unrestricted Revenue Funds
189,871
**_Restricted funds:-_**
Model Cell Biobank
16,738
**206,609**|
**Movement in**
**funds in 2022**
**See Note 14**
**£**
26,803
**26,803**
3,756
**3,756**
**30,559**
**13**
**Expenditure**
**2022**
**£**
(163,068)
(12,982)
**(176,050)**|**£**
**-**
**-**
-
**-**
**-**
**Gains &**
**Losses**
**2022**
**£**
-
-
**-**
**Transfers**
**between**
**funds in 2022**|**Funds carried**
**forward to**
**2023**
**£**
**£**
**285,330**
**285,330**
**285,330**
**285,330**
**31,517**
**31,517**
**31,517**
**31,517**
**316,847**
**316,847**
**Movement**
**Movement**
**in funds**
**in funds**
**2022**
**2022**
**£**
**£**
**26,803**
**26,803**
**3,756**
**3,756**
**30,559**
**30,559**
**Funds carried**
**forward to**
**2023**| |---|---|---|---| 21 ## **Leukaemia & Myeloma Research UK Ltd** ## **Notes to the Accounts for the year ended 31 March 2022** ## **15 The purposes for which the funds** _**Unrestricted and designated funds:-**_ Unrestricted Revenue Funds These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, research grants, and, subject to charity legislation, are free from all restrictions on their use. _**Restricted funds:-**_ Model Cell Biobank The purpose of these funds is described under the accounting policy. ## **16 Ultimate controlling party** The charity is under the control of its legal members. Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member. 22 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** ## _**This analysis is classsified by conventional nominal descriptions and not by activity.**_ ## **17 Donations, Grants and Legacies** **----- Start of picture text -----**
|||||| |---|---|---|---|---| |Current year|Current year|Current year|Prior Year| |Unrestricted|Restricted|Total Funds|Total Funds| |Funds|Funds| |2022|2022|2022|2021| |£|£|£|£| |Donations and gifts from individuals| |Small donations individually less than £1000|7,410|-|7,410|5,274| |Refunds from HMRC on gift aided donations|68|-|68|-| |Stripe direct donations|7,995|-|7,995|6,061| |Briggs Equipment Ltd|-|-|-|1,000| |Facebook|3,782|-|3,782|6,378| |-| |Just Giving|17,827|17,827|11,847| |Kiltwalk|1,193|-|1,193|-| |-| |In Memory|9,028|9,028|9,135| |Fundraising Support|-|-|-|1,731| |Muchloved|3,545|-|3,545|2,522| |-| |Virgin Money Giving|2,453|2,453|2,880| |-|-| |Giving.com|2,379|2,379| |-|-| |Paypal Giving|1,066|1,066| |Total donations and gifts from|56,746|-|56,746|46,828| |individuals| **----- End of picture text -----**
All the donations and gifts in the prior year were unrestricted. ## **Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis** **----- Start of picture text -----**
||||| |---|---|---|---| |Prior Year|Prior Year|Prior Year| |Unrestricted|Restricted|Total Funds| |Funds|Funds| |2021|2021|2021| |£|£|£| |Prior year|45,097|1,731|46,828| **----- End of picture text -----**
23 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** |**Legacies receivable**
**Legacies receivable**
Small legacies individually less than
£1000
Mrs Mary Dallas
Mrs Beryl Mary Round
Mayo Wynne Baxter Solicitors
Withers LLP
Macmillans Solicitors LLP
**Legacies receivable - Prior Year analysis**
**Prior year**
**Total legacies receivable**|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
-
100
40,784
64
-
-
**40,948**
**Prior Year**
**Unrestricted**
**Funds**
**2021**
**£**
41,756|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
-
-
-
-
-
**-**
**Prior Year**
**Restricted**
**Funds**
**2021**
**£**
-|**Current year**
**Total Funds**
**2022**
**£**
**-**
**100**
**40,784**
**64**
**-**
**-**
**40,948**
**Prior Year**
**Total Funds**
**2021**
**£**
**41,756**|**Prior Year**
**Total Funds**
**2021**
**£**
-
-
-
9,771
25,165
6,820
**41,756**| |---|---|---|---|---| 24 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** ## **Revenue grants from government and public bodies** |Small grants individually less than
£1000
M&G Plc Charities Trust
Arcobaleno Cancer Trust
LCVS Community Impact Fund
Albert Hunt Trust
The Grace Trust
L&R Gilley Charitable Trust
Tesco/Groundwork UK
The Constance Paterson Charitable
Trust
The Ian Askew Charitable Trust
Charities Trust AVIVA
Crowdfunder
The Caron Keating Foundation
The Hospital Saturday Fund
CAF/Box Power Foundation
The Thomas Sivewright Catto
Charitable Trust
Sir Cliff Richard
Arnold Clark
**Total public sector revenue grants**
**Revenue grants from government and**
**public bodies**|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
-
-
-
-
-
-
-
-
-
1,000
3,268
247
-
-
10,000
-
1,000
1,000
**16,515**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
1,240
-
-
-
-
-
2,500
-
2,500
-
-
-
3,000
2,000
-
1,000
-
-
**12,240**|**Current year**
**Total Funds**
**2022**
**£**
**1,240**
**-**
**-**
**-**
**-**
**-**
**2,500**
**-**
**2,500**
**1,000**
**3,268**
**247**
**3,000**
**2,000**
**10,000**
**1,000**
**1,000**
**1,000**
**28,755**|**Prior Year**
**Total Funds**
**2021**
**£**
1,350
1,900
3,000
1,000
1,000
1,500
-
1,000
-
-
12,066
5,000
-
-
-
-
-
-
**27,816**| |---|---|---|---|---| ## **Revenue grants from government and public bodies - Prior Year analysis** |**Prior Year**|**Prior Year**
**Unrestricted**
**Funds**
**2021**
**£**
21,266|**Prior Year**
**Restricted**
**Funds**
**2021**
**£**
6,550|**Prior Year**
**Total Funds**
**2021**
**£**
**27,816**| |---|---|---|---| 25 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** **----- Start of picture text -----**
Current year Current year Current year Prior Year
Unrestricted Restricted Total Funds Total Funds
Funds Funds
2022 2022 2022 2021
£ £ £ £
Revenue grants and donations from non
public bodies
- -
Lunya Limited 8,000 8,000
- -
Fundraising Support Ltd 4,178 4,178
Total private sector revenue grants 8,000 4,178 12,178 -
Donated goods and services
Current year Current year Current year Prior Year
Unrestricted Restricted Total Funds Total Funds
Funds Funds
2022 2022 2022 2021
£ £ £ £
Donated goods and services
Small gifts individually less than £1000 - - - 12,000
Total donated goods and services - - - 12,000
Donated goods and services - Prior Year analysis
Prior Year Prior Year Prior Year
Unrestricted Restricted
Total Funds
Funds Funds
2021 2021 2021
£ £ £
Prior Year 12,000 - 12,000
Total Donations, Grants and Legacies
Unrestricted Restricted Current Year Prior Year
Funds Funds Total Funds Total Funds
Current year
2022 2022 2022 2021
£ £ £ £
Total Donations, Grants and
A1 122,209 16,418 138,627 128,400
Legacies
All the donations and gifts in the prior year were unrestricted.
Unrestricted Restricted Prior Year
Prior year Funds Funds Total Funds
2021 2021 2021
£ £ £
Total Donations, Grants and
A1 120,119 8,281 128,400
Legacies
**----- End of picture text -----**
26 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** |**18 Income from charitable activities - Trading Activities**
**_Current year_**
**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
**Primary purpose and ancillary trading**
17,526
**17,526**
**19**
**Current year**
**_Current year_**
**Unrestricted**
**Funds**
**2022**
**£**
Total income from charitable trading
17,526
**Total from charitable activities**
**A2**
**17,526**
**Income from charitable activities - Prior Year analysis**
**Prior Year**
**_Prior year_**
**Unrestricted**
**Funds**
**2021**
**£**
Total income from charitable trading
7,241
**7,241**
**20 Investment income**
**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
Bank Interest Receivable
27
**Total investment income**
**A4**
**27**
**Total Primary purpose and ancillary**
**trading**
Sale of goods and services in accordance
with the charity's objects
**Total Income from charitable activities**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
320
**320**
**Current year**
**Restricted**
**Funds**
**2022**
**£**
320
**320**
**Prior Year**
**Restricted**
**Funds**
**2021**
**£**
-
**-**
**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
**-**|**Current year**
**Total Funds**
**2022**
**£**
**17,846**
**17,846**
**Current year**
**Total Funds**
**2022**
**£**
**17,846**
**17,846**
**Prior Year**
**Total Funds**
**2021**
**£**
7,241
**7,241**
**Current year**
**Total Funds**
**2022**
**£**
**27**
**27**|**Prior Year**
**Total funds**
**2021**
**£**
7,241
**7,241**
**Prior Year**
**Total Funds**
**2021**
**£**
7,241
**7,241**
**Prior Year**
**Total Funds**
**2021**
**£**
187
**187**| |---|---|---|---| 27 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** |**21 Other income and gains**
**_Current year_**
**Total other income**
**A5**
**Other income and gains - Prior year analysis**
**_Prior Year_**
**Total other income**
**A5**
Royalties from the exploitation of
intellectual property rights
Sundry other income
Royalties from the exploitation of
intellectual property rights
Sundry other income|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
50,000
109
**50,109**
**Prior Year**
**Unrestricted**
**Funds**
**2021**
**£**
50,085
2,391
**52,476**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
-
**-**
**Prior Year**
**Restricted**
**Funds**
**2021**
**£**
-
-
**-**|**Current year**
**Total Funds**
**2022**
**£**
**50,000**
**109**
**50,109**
**Prior Year**
**Total Funds**
**2021**
**£**
**50,085**
**2,391**
**52,476**|**Prior Year**
**Total Funds**
**2021**
**£**
50,085
2,391
**52,476**| |---|---|---|---|---| 28 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** ## **22 Expenditure on charitable activities - Direct spending** |**Current year**
**_Current Year_**
**Unrestricted**
**Funds**
**2022**
**£**
1,930
10,098
24,636
**Total direct spending**
**B2a**
**36,664**
**Prior Year**
**_Prior Year_**
**Unrestricted**
**Funds**
**2021**
**£**
2,150
7,991
22,180
**Total direct spending**
**B2a**
**32,321**
**Expenditure on charitable activities - Charitable trading**
**Current year**
**_Current Year_**
**Unrestricted**
**Funds**
**2022**
**£**
**11,198**
**Total charitable trading costs**
**B2b**
**11,198**
Travel and Subsistence - Charitable
Activities
Cost of goods for primary purpose trading -
Including movement in stock for goods
made by beneficiaries
Costs of activities and events
Costs of activities and events
Consultancy and professional support
Consultancy and professional support
Travel and Subsistence - Charitable
Activities|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
10,585
-
**10,585**
**Prior Year**
**Restricted**
**Funds**
**2021**
**£**
-
1,823
-
**1,823**
**Current year**
**Restricted**
**Funds**
**2022**
**£**
**-**
**-**|**Current year**
**Total Funds**
**2022**
**£**
**1,930**
**20,683**
**24,636**
**47,249**
**Prior Year**
**Total Funds**
**2021**
**£**
**2,150**
**9,814**
**22,180**
**34,144**
**Current year**
**Total Funds**
**2022**
**£**
**11,198**
**11,198**|**Prior Year**
**Total Funds**
**2021**
**£**
**2,150**
**9,814**
**22,180**
**34,144**
**Prior Year**
**Total Funds**
**2021**
**£**
**3,179**
**3,179**| |---|---|---|---| ## **23 Expenditure on charitable activities - Charitable trading** ## **24 Expenditure on charitable activities- Grant funding of activities** |**_Current Year_**
**Total grantmaking costs**
**B2c**
Grants made to organisations|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
24,251
**24,251**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
**-**|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2022**
**2021**
**£**
**£**
**24,251**
**35,000**
**24,251**
**35,000**| |---|---|---|---| 29 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** ## **25 Support costs for charitable activities** |**Current year**
**Current year**
**_Current Year_**
**Unrestricted**
**Funds**
**Restricted**
**Funds**
**2022**
**2022**
**£**
**£**
**_Premises Expenses_**
Rates and water charges
249
-
Rent and rates
23,206
-
414
-
216
-
4,098
-
428
-
**_Administrative overheads_**
2,042
323
483
99
416
-
Shipping, freight and delivery
840
-
Membership subscriptions
7,381
-
3,168
-
1,058
-
1,426
906
12,433
1,069
325
-
**_Professional fees paid to advisors other than the auditor or examiner_**
1,080
-
21,528
-
-
-
**_Financial costs_**
24
-
625
-
**Support costs before reallocation**
**81,440**
**2,397**
**Total support costs - Current Year**
**81,440**
**2,397**
The basis of allocation of costs between activities is described under accounting policies
Bank charges
Accountancy fees other than
examination or audit fees
Management fees
Stationery and printing
Hire of equipment
Light heat and power
Telephone, fax and internet
Postage
Cleaning and waste management
Property insurance
Equipment,repairs,expenses and maintenance
Software licences and expenses
Premises repairs, renewals and
maintenance
Advertising and marketing
Equipment expenses
Depreciation & Amortisation in total for
Other legal and professional|**Current year**
**Total Funds**
**2022**
**£**
**249**
**23,206**
**414**
**216**
**4,098**
**428**
**2,365**
**582**
**416**
**840**
**7,381**
**3,168**
**1,058**
**2,332**
**13,502**
**325**
**1,080**
**21,528**
**-**
**24**
**625**
**83,837**
**83,837**|**Prior Year**
**Total Funds**
**2021**
**£**
**-**
**17,050**
**522**
**690**
**423**
**-**
**2,222**
**635**
**949**
**-**
**5,564**
**2,670**
**1,031**
**1,409**
**10,798**
**-**
**1,080**
**16,210**
**104**
**134**
**625**
**62,116**
**62,116**| |---|---|---| 30 ## **Leukaemia & Myeloma Research UK Ltd** ## **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** |**_Prior Year_**
**_Premises Expenses_**
Rent and rates
Light heat and power
Cleaning and waste management
Premises repairs, renewals and
maintenance
**_Administrative overheads_**
Telephone, fax and internet
Postage
Stationery and printing
Membership subscriptions
Equipment expenses
Hire of equipment
Software licences and expenses
Advertising and marketing
Accountancy fees other than
examination or audit fees
Management fees
Other legal and professional
**_Financial costs_**
Bank charges
Depreciation & Amortisation in
**_Support costs before_**
**Total support costs - Prior Year**
**_Professional fees paid to advisors other than the_**
**_auditor or examiner_**|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
17,050
522
690
423
1,899
635
949
5,564
2,670
1,031
496
10,592
1,080
16,210
104
134
625
**60,674**
**60,674**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
-
-
-
323
-
-
-
-
-
913
206
-
-
-
-
-
**1,442**
**1,442**|**Prior Year**
**Total Funds**
**2021**
**£**
**17,050**
**522**
**690**
**423**
**2,222**
**635**
**949**
**5,564**
**2,670**
**1,031**
**1,409**
**10,798**
**1,080**
**16,210**
**104**
**134**
**625**
**62,116**
**62,116**| |---|---|---|---| The basis of allocation of costs between activities is described under accounting policies 31 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** ## **26 Other Expenditure - Governance costs** |**_Current Year_**
Independent Examiner's fees
**Total Governance costs**|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
420
**420**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
**-**|**Current year**
**Total Funds**
**2022**
**£**
**420**
**420**|**Prior Year**
**Total Funds**
**2021**
**£**
**420**
**420**| |---|---|---|---|---| All the expenditure in the prior year was unrestricted. ## **27 Total Charitable expenditure** |**_Current Year_**
Total direct spending
**B2a**
Total charitable trading costs
**B2b**
Total grantmaking costs
**B2c**
Total support costs
**B2d**
Total Governance costs
**B2e**
**Total charitable expenditure**
**B2**|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
36,664
11,198
24,251
81,440
420
**153,973**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
10,585
-
-
2,397
-
**12,982**|**Current year**
**Total Funds**
**2022**
**£**
**47,249**
**11,198**
**24,251**
**83,837**
**420**
**166,955**|**Prior Year**
**Total Funds**
**2021**
**£**
**34,144**
**3,179**
**35,000**
**62,116**
**420**
**134,859**| |---|---|---|---|---| |**_Prior Year_**
Total direct spending
**B2a**
Total charitable trading costs
**B2b**
Total grantmaking costs
**B2c**
Total support costs
**B2d**
Total Governance costs
**B2e**
**Total charitable expenditure**
**B2**|**Prior Year**
**Unrestricted**
**Funds**
**2021**
**£**
32,321
3,179
35,000
60,674
420
**131,594**|**Prior Year**
**Prior Year**
**Restricted**
**Funds**
**Total Funds**
**2021**
**2021**
**£**
**£**
1,823
**34,144**
-
**3,179**
-
**35,000**
1,442
**62,116**
-
**420**
**3,265**
**134,859**| |---|---|---| 32 ## **Leukaemia & Myeloma Research UK Ltd** **Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015** ## **28 Expenditure on raising funds and costs of investment management** |**_Current Year_**
Agent's costs for fundraising
Fundraising publicity & marketing
Cost of fundraising activities
Fundraising trading costs
**Total fundraising costs**
**B1**|**Current year**
**Unrestricted**
**Funds**
**2022**
**£**
4,945
480
2,764
906
**9,095**|**Current year**
**Restricted**
**Funds**
**2022**
**£**
-
-
-
-
**-**|**Current year**
**Prior Year**
**Total Funds**
**Total Funds**
**2022**
**2021**
**£**
**£**
**4,945**
**3,000**
**480**
**-**
**2,764**
**250**
**906**
**277**
**9,095**
**3,527**| |---|---|---|---| All the expenditure in the prior year was unrestricted. 33